These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 1947381)

  • 1. SMS 201-995 and thyroid function in acromegaly: acute, intermediate and long-term effects.
    Christensen SE; Weeke J; Kaal A; Harris AG; Orskov H
    Horm Metab Res; 1992 May; 24(5):237-9. PubMed ID: 1398464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR.
    Taboada GF; Correa LL; de Oliveira Machado E; van Haute FR; Casini AF; Balarini GA; Neto LV; Calixto L; Calixto C; Gadelha MR
    Growth Horm IGF Res; 2007 Feb; 17(1):77-81. PubMed ID: 17314058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acromegaly with octreotide: effectiveness and tolerability of its pulsatile administration by portable pump.
    Giusti M; Cuttica CM; Cariola G; Valenti S; Sessarego P; Giordano G
    Recenti Prog Med; 1995 May; 86(5):189-94. PubMed ID: 7604174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones.
    George SR; Hegele RA; Burrow GN
    Clin Invest Med; 1987 Jul; 10(4):309-15. PubMed ID: 2888554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of repeated injections of sandostatine, with increasing doses, in the treatment of 40 acromegalics. French Group for the study of Sandostatine in Acromegaly].
    Ann Endocrinol (Paris); 1988; 49(4-5):323-30. PubMed ID: 3059976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postprandial exocrine pancreatic function during long-term treatment with the somatostatin analogue SMS 201-995 in acromegalic patients.
    Van Liessum PA; Hopman WP; Pieters GF; Smals AG; Tangerman A; Jansen JB; Rosenbusch G; Lamers CB
    Eur J Clin Invest; 1990 Aug; 20(4):348-53. PubMed ID: 2121494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients.
    Halperin I; Nicolau J; Casamitjana R; Sesmilo G; Serra-Prat M; Palomera E; Puig-Domingo M
    Horm Metab Res; 2008 Jun; 40(6):422-6. PubMed ID: 18393173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
    Pagani G; Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Ghilardi G; Cortesi L; Pedroncelli A; Tonnarelli GP
    Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Trials of acute treatment with SMS 201-995 in acromegalics].
    Santos C; García-Luna PP; Acosta D; Pumar A; Pereira JL; Gavilán I; Cuberta F; García de Pesquera F; Astorga R
    Rev Clin Esp; 1991 Jul; 189(3):110-4. PubMed ID: 1947381
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.